Ensysce Biosciences IncENSC
Price$0.40Intrinsic value$0.3123% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $5.1M-2.7% YoYTTM through 31 Dec 2025
Net Income -$10.2MTTM through 31 Dec 2025
Free Cash Flow -$7.9MTTM through 31 Dec 2025

Margins

Current
Operating Margin-202.0%
Net Margin-200.8%

Returns

-353.5%ROE
-136.6%ROA

Balance Sheet Health

Debt / Equity0.11x
Current Ratio1.59x
Net Debt-$4Mnet cash position
Cash & Equivalents$4.3M

Quality Metrics

FCF Margin-156.4%
Earnings-Beat Rate75.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Federal Grants$5.1M-2.7%
View details

Continued reliance on non-dilutive federal grant funding to support early-stage clinical trials.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.